Clinical trials
Polycystic Kidney Disease clinical trials
Below are recruiting polycystic kidney disease clinical trials, each written for real people, not researchers. We’re tracking 70 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04782258RecruitingPhase 3
Testing the safety of tolvaptan in children with ARPKD
This trial is for children from 28 days old up to 18 years who have a rare kidney disease called ARPKD. It will test if the drug tolvaptan is safe for them. The study helps find new treatment options for kids with this condition.
Washington D.C., District of ColumbiaAges 4 weeks–18 years - NCT04344769Recruiting
Studying how a kidney-protecting pathway works in ADPKD
This study looks at how the body’s “Nrf2 response” works in people with autosomal dominant polycystic kidney disease (ADPKD). It may help researchers better understand disease biology and future treatments by comparing kidney-related signals in ADPKD patients and healthy volunteers.
Rochester, MinnesotaAges 18–30 - NCT03901521Enrolling by invitation
Biobank for people with autosomal dominant polycystic kidney disease
This study collects samples and health information from adults with autosomal dominant polycystic kidney disease (ADPKD) who are having their own kidney removed. It helps researchers learn more about ADPKD and its genetic changes to support future treatments.
New York, New YorkAges 18–100 - NCT01401998Recruiting
Study collecting information from people with ARPKD
This study looks at medical records, imaging, and genetic testing for people with autosomal recessive polycystic kidney disease (ARPKD). It may help researchers better understand the condition and how it affects the liver and kidneys.
Washington D.C., District of ColumbiaAges Up to 18 years - NCT06322056Recruiting
Lower blood pressure and cholesterol targets for advanced kidney disease
This trial tests whether keeping blood pressure and cholesterol at lower-than-usual levels can help slow the decline of kidney function in people with advanced chronic kidney disease. If you have moderately to severely reduced kidney function and meet certain blood pressure and cholesterol criteria, you may be able to join.
SeoulAges 19 years+ - NCT07419828RecruitingPhase 3
Study of HRS-1780 for chronic kidney disease
This trial tests an investigational drug called HRS-1780 in people with chronic kidney disease. It aims to see if the drug can help slow kidney decline and is safe to use.
Nanjing, JiangsuAges 18–80 - NCT07405216RecruitingPhase 4
SGLT2 inhibitors for teens with early kidney disease
This trial tests whether a type of medicine called SGLT2 inhibitors can help teenagers with early-stage chronic kidney disease. It looks at how safe and effective these drugs are for slowing down kidney damage.
Aguascalientes, AguascalientesAges 14–18 - NCT07239570RecruitingPhase 4
Using biomarkers to personalize kidney disease treatment
This study tests if matching treatments to your specific kidney disease markers can better protect your kidneys. It looks at how well Finerenone, Dapagliflozin, and Semaglutide work alone or in a sequence.
HerlevAges 18–75 - NCT06600412RecruitingPhase 2
Testing R3R01 for protein in urine from diabetic kidney disease
This trial tests if a new drug, R3R01, can help reduce protein leaking into the urine in people with diabetic kidney disease. It may offer a new option for managing kidney health.
Copenhagen, CopenhagenAges 18 years+ - NCT06256991RecruitingPhase 4
Potassium management for kidney health
This study tests if careful potassium management can help people with chronic kidney disease (CKD) safely take higher doses of blood pressure medicines called ACE inhibitors or ARBs, which are known to protect the kidneys. You may be eligible if you have moderate to advanced CKD and are already on a moderate dose of one of these medications.
GroningenAges 18 years+ - NCT06202235Recruiting
Magnetic resonance imaging for chronic kidney disease
This trial uses a special MRI technique called multifrequency magnetic resonance elastography (MRE) to see if it can help evaluate chronic kidney disease. It may provide a non-invasive way to monitor kidney health without needing a biopsy.
Shenyang, LiaoningAges 18–65 - NCT05732727RecruitingPhase 3
Stronger BP lowering using diuretics in kidney disease
This Phase 3 trial compares a plan that uses diuretics (water pills) to lower blood pressure more, versus usual blood pressure care, in people with uncontrolled hypertension and moderate-to-severe chronic kidney disease. It may help your blood pressure control while monitoring safety closely because kidney function changes how medicines work.
AngersAges 18 years+ - NCT02848131Enrolling by invitationPhase 2
Testing dasatinib and quercetin in diabetes-related kidney disease
This study tests whether two medicines (dasatinib and quercetin) can affect “cell aging” in people with chronic kidney disease related to diabetes. You may be asked to take pills for a short period and complete follow-up visits to measure how your body responds.
Jacksonville, FloridaAges 40–80 - NCT07851454Recruiting
Walnuts for heart and kidney health in chronic kidney disease
This trial tests whether eating walnuts every day can help protect the heart and kidneys in people with chronic kidney disease. It may help improve blood pressure, cholesterol, and blood sugar control.
Reus, TarragonaAges 45–75 - NCT06147414Recruiting
Blood test for genetic disorders in pregnancy
This study tests a safer blood test to check for certain genetic disorders during pregnancy, instead of an invasive procedure like amniocentesis. It's for pregnant women who are at risk of passing on a known genetic condition.
ParisAges 18 years+ - NCT04111692Recruiting
Watching foam treatment for cysts in autosomal polycystic disease
This study follows adults with inherited kidney and/or liver cysts that are causing symptoms to see how a foam sclerotherapy procedure may help and what outcomes happen over about a year. You may be eligible if you have a few sizable, specific-type cysts and can safely attend follow-up visits.
Rochester, MinnesotaAges 18–100 - NCT07788014RecruitingPhase 1
Testing a new medicine for healthy adults
This study tests a new investigational drug called GV-100 to see how safe it is and how the body handles it. It is for healthy adults and will be given in different doses to find the best one.
Adelaide, South AustraliaAges 18–65 - NCT07792408RecruitingPhase 1
Study of VX-407 and oral contraceptive interaction
This study tests how a new drug, VX-407, affects the levels of a combined oral contraceptive in your body. Participants must be healthy adults aged 18 to 65 with a certain body weight and BMI.
MontrealAges 18–50 - NCT07745920Recruiting
An online program for depression in people with adpkd
This study tests an internet-based program to help manage depression symptoms in people with ADPKD. The program may be a convenient way to get support for your mood without traveling to a clinic.
Rochester, MinnesotaAges 18–70 - NCT06714006RecruitingPhase 1
Testing safety of PYC-003 for ADPKD
This study is testing a new investigational medicine called PYC-003 for people with autosomal dominant polycystic kidney disease (ADPKD). It is one of the first studies in humans, so the main goal is to see if the medicine is safe and tolerable. The study is for people with a specific genetic cause (PKD1 mutation) and with certain kidney imaging types.
Southport, Gold CoastAges 18–65 - NCT01873235Recruiting
Study for adults with confirmed polycystic kidney disease
This study enrolls adults with autosomal dominant polycystic kidney disease (ADPKD) to better understand the disease and its related changes in the body. It may help researchers find improved ways to track the condition and support future treatments.
Baltimore, MarylandAges 18 years+ - NCT05373264RecruitingPhase 3
Hydrochlorothiazide to help polycystic kidney disease and quality of life
This Phase 3 study tests whether hydrochlorothiazide can help people with autosomal dominant polycystic kidney disease (ADPKD) and improve quality of life. It also looks at whether it affects kidney health while you stay on your current ADPKD-related treatment.
GrazAges 18–80 - NCT04630613Recruiting
Studying NOX4 markers in young adults with ADPKD
This study measures a kidney-related marker (NOX4) and other blood/urine signals in people with early-stage ADPKD to better understand disease activity. It may help researchers identify who is likely to progress and why, though it may not be a treatment study.
Rochester, MinnesotaAges 15–40 - NCT04338048Recruiting
Study for autosomal dominant polycystic kidney disease
This study enrolls people who have been diagnosed with autosomal dominant polycystic kidney disease (ADPKD), a genetic kidney condition that can cause kidney cysts. It aims to learn about this specific form of the disease so better care is possible for the right patients.
Washington D.C., District of ColumbiaAges Up to 18 years
Hear when a new Polycystic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for polycystic kidney disease?
- Yes. Clin2 currently lists 70 recruiting polycystic kidney disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a polycystic kidney disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a polycystic kidney disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.